MYRIAD GENETICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MYRIAD GENETICS, INC. (MYGN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $8.70 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-11-07
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $300.00K, a 99.02% decline year-over-year.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $2.40M, a 84.52% decline year-over-year.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $6.00M.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $800.00K, a 38.46% decline year-over-year.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $46.90M, a 12.20% increase from fiscal 2021.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $41.80M.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $74.50M.
- MYRIAD GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.70M derived: sum of 2 quarters · filed 2023-11-07 | $8.70M 10-Q · filed 2023-11-07 | $9.50M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $8.40M 10-Q · filed 2023-08-04 | $9.20M derived: sum of 3 quarters · filed 2023-08-04 | $39.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $6.00M 10-Q · filed 2023-05-04 | $6.80M derived: sum of 2 quarters · filed 2023-05-04 | $37.40M derived: sum of 3 quarters · filed 2023-11-07 | $52.90M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $31.40M derived: sum of 2 quarters · filed 2023-11-07 | $46.90M derived: sum of 3 quarters · filed 2023-11-07 | $46.90M 10-K · filed 2023-03-01 |
| 2022-09-30 | $30.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $46.10M derived: sum of 2 quarters · filed 2023-11-07 | $46.10M 10-Q · filed 2023-11-07 | $47.40M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $15.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $15.50M 10-Q · filed 2023-08-04 | $16.80M derived: sum of 3 quarters · filed 2023-08-04 | $16.80M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $1.30M derived: sum of 2 quarters · filed 2023-05-04 | $1.30M derived: sum of 3 quarters · filed 2023-05-04 | $39.10M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.30M derived: sum of 2 quarters · filed 2023-03-01 | $39.10M derived: sum of 3 quarters · filed 2023-03-01 | $41.80M 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $37.80M derived: sum of 2 quarters · filed 2022-11-02 | $40.50M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $37.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $40.50M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $2.70M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $74.50M 10-K · filed 2023-03-01 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2019-06-30 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |